Clinical trial NCT02251873: Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers
Official title: An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to characterise the effects of concurrent tipranavir (TPV) and ritonavir (RTV) administration on the single dose pharmacokinetics of didanosine (ddI), to characterise the effects of single-dose ddI on the pharmacokinetics of TPV and RTV and to assess the short-term safety of this combination


Eligibility criteria: Inclusion Criteria:

* Healthy male or female subjects as determined by results of screening
* Female subjects were not lactating and not of child bearing potential as defined by surgically sterile or post menopausal (no periods for at least 12 months and elevated follicle stimulating hormone (FSH) with low estradiol and no estrogen supplementation). Females were to use barrier contraception (e.g. condoms) for at least one month prior to administration of study medication, during the study and at least one month after release from the study. Women were to have negative pregnancy tests
* Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
* Age \>=18 and \<=60 years
* Body mass index (BMI) \>=18.5 and \<=29.9 kg/m2

Exclusion Criteria:

* Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
* History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders, including a clinical history of viral hepatitis, or serological evidence of active Hepatitis B, Hepatitis C, or HIV infection
* History of orthostatic hypotension, fainting spells and blackouts
* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* Chronic or relevant acute infections
* History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator including study drugs
* Intake of drugs with a long half-life (\> 24 hours) or enzyme altering drug within 1 month prior to administration of study drugs
* Use of any drugs that might have influenced the results of the trial within 10 days prior to administration or during the trial (in addition to specific medication prohibitions mentioned in exclusion criteria above)
* Use of grapefruit or grapefruit juice, alcohol, green tea, methylxanthine-containing products or tobacco within one week of study drug administration
* Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
* Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on trial days
* Alcohol abuse (\> 60 g/day)
* Drug abuse
* Blood or plasma donation within 1 month prior to administration or during the trial
* Excessive physical activities within 5 days prior to administration or during the trial
* Following specific laboratory findings: activated partial thromboplastin time (aPTT), prothrombin time international normalised ratio (INR), aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl-transferase (GGT), amylase, lipase, or triglyceride above the normal range
* Any other laboratory value outside the clinically accepted reference range and of clinical relevance
* History of any familial bleeding disorder
* Inability to swallow multiple large capsules
* Inability to comply with dietary regimen of study centre
* Inability to comply with investigator's instructions

Primary outcomes:
measure: (AUC 0-12) Area under the plasma concentration time curve from 0-12 hours
timeFrame: up to 12 hours after dose administration
measure: Cmax (Maximum measured concentration of the analyte in plasma)
timeFrame: up to 12 hours after dose administration
measure: (C6h) drug concentration in plasma at 6 hours after drug administration
timeFrame: up to 6 hours after dose administration
measure: (C12h) drug concentration in plasma at 12 hours after drug administration
timeFrame: up to 12 hours after dose administration
measure: Cnh (plasma concentration n hours after drug administration)
timeFrame: up to 12 hours after dose administration
Secondary outcomes:
measure: Cmax,ss (maximum plasma concentration at steady state)
timeFrame: up to 12 hours after dose administration
measure: MRT (mean residence time)
timeFrame: up to 12 hours after dose administration
measure: Tmax (time to the maximum plasma concentration)
timeFrame: up to 12 hours after dose administration
measure: CL/F (apparent oral clearance)
timeFrame: up to 12 hours after dose administration
measure: Vz/F (apparent volume of distribution)
timeFrame: up to 12 hours after dose administration
measure: t½ (Terminal half-life of the analyte in plasma)
timeFrame: up to 12 hours after dose administration
measure: Number of subjects with adverse events
timeFrame: up to 40 days
measure: Number of subjects with abnormal changes in laboratory parameters
timeFrame: up to 40 days
Other outcomes:
Locations:
Study officials:
References: